1.Discussion on the commonalities of scalp acupuncture schools and the feasibility of a unified scalp acupuncture protocol.
Xiaomeng HU ; Chang SUN ; Yan LI ; Xitong MO ; Peng YAN ; Sixuan CHEN ; Gangqi FAN
Chinese Acupuncture & Moxibustion 2025;45(1):110-122
The data of 44 scalp acupuncture schools are collected to analyze their commonalities in theoretical foundations, needling sites, techniques, and indications. The integration of these characteristics into an optimized, unified scalp acupuncture protocol has become an inevitable trend. The paper discusses the potential for a unified scalp acupuncture protocol from aspects such as theoretical unification, the relationships between point areas, lines, and sites, and needle numbers. It also explores the primary issues and solutions involved in unifying scalp acupuncture protocols, providing a reference for standardization and unification in scalp acupuncture protocol.
Scalp
;
Humans
;
Acupuncture Therapy/methods*
;
Acupuncture Points
2.Reflections and suggestions on the researches of acupuncture-moxibustion for idiopathic facial palsy.
Sixuan CHEN ; Yan LI ; Xitong MO ; Peng YAN ; Xiaomeng HU ; Chang SUN ; Gangqi FAN
Chinese Acupuncture & Moxibustion 2025;45(3):379-384
This article analyzes the current status of the researches on acupuncture-moxibustion for idiopathic facial palsy (Bell's palsy). Acupuncture-moxibustion is widely applied in treatment of Bell's palsy and the relevant researches are enriched. But the hierarchical discussion on the effectiveness is reported inadequately. Consequently, the necessity and advantages of acupuncture-moxibustion are hardly prominent. Besides, the safety of acupuncture-moxibustion in treatment is not fully explored. The common shortcomings are presented in professional study and statistical designs, and the quality of the evidences is not high. The recommendation strength of acupuncture-moxibustion is weak in international guidelines. The crucial questions are not deeply discussed, and there are lack of the recognized optimal protocol in clinical practical guidelines. It is suggested that the researches should improve the evaluation of the disease itself that may affect the prognosis of Bell's palsy, such as location, conditions and duration of illness, basic diseases and syndrome/pattern differentiation. The effect of acupuncture-moxibustion should be verified hierarchically, the questions on safety should be emphasized, the quality of study should be improved, the staging of treatment should be specified and the effect of acupuncture-moxibustion should be evaluated in multi-dimensions, and the elements of acupuncture-moxibustion should be optimized systematically in the aspects of timing, acupoint selection, needle devices, manipulation, intervention measures and regimen composition. So as to promote the research of acupuncture-moxibustion for Bell's palsy to a new process.
Humans
;
Acupuncture Therapy
;
Moxibustion
;
Bell Palsy/therapy*
3.FAN Gangqi's experience in "four-dimensional" diagnosis and treatment of migraine with acupuncture and moxibusition.
Sixuan CHEN ; Chang SUN ; Xiaomeng HU ; Xitong MO ; Yan LI ; Peng YAN ; Yuxin ZHANG ; Gangqi FAN
Chinese Acupuncture & Moxibustion 2025;45(9):1299-1304
The paper introduces Professor FAN Gangqi's clinical experience in treatment of migraine. Regarding the syndrome/pattern differentiation of TCM, a four-approach framework is established, identifying the nature of illness, analyzing the syndrome/pattern and pathogenesis, determining the stage of illness, and identifying body constitution. In treatment, the principle of treatment is determined in line with syndrome/pattern differentiation, so as to ensure the therapeutic effect by means of "four dimensions". The acupuncture regimens are formulated in terms of the illness stages, "strong needling stimulation in acute stage for analgesia, and needle retaining in chronic stage for long-term effect". "Focusing on neuovascular pathway" is the effective approach to treatment of migraine with acupuncture and moxiubstion. The clinical holistic model by combining acupuncture with medication is advocated because that "the single acupuncture is weak in therapeutic effect, but with medication combined, the effect is enhanced". The different acupuncture techniques are provided comprehensively in treatment of migraine such as horizontal and row-like needling, collateral needling at Taiyang (EX-HN5), acupuncture at Sankong (Yuyao [EX-HN4], Sibai [ST2] and Jiachengjiang [Extra]), acupoint injection at Tianyou (TE16) and Renying (ST9), and acupoint embedding therapy at Fengchi (GB20).
Humans
;
Migraine Disorders/diagnosis*
;
Acupuncture Therapy
;
Moxibustion
;
Acupuncture Points
;
Female
;
Male
;
Adult
4.Difference in Adverse Reactions between Colorectal Cancer Patients with or without Spleen-kidney Yang Deficiency Syndrome after Oxaliplatin-containing Chemotherapy
Yifan LI ; Yipang ZHAO ; Boyuan HAN ; Yixuan LIU ; Sixuan XING ; Wenjing YANG ; Qing ZHANG
Journal of Traditional Chinese Medicine 2024;65(19):2010-2017
ObjectiveTo compare the difference in adverse reactions after oxaliplatin-containing chemotherapy between colorectal cancer patients with or without spleen-kidney yang deficiency syndrome. MethodsA retrospective study was conducted using the electronic medical records of Beijing Hospital of Traditional Chinese Medicine, Capital Medical University. A total of 483 colorectal cancer patients from January 1, 2009 to December 31, 2022 were selected. Patients were divided into two groups based on their syndrome types, that was spleen-kidney yang deficiency syndrome (SKYDS) group (130 cases) and non-SKYDS group (353 cases). The incidence of adverse reactions including gastrointestinal reactions, liver damage, bone marrow suppression, and peripheral neurotoxicity after completing 2, 4, 6, and more than 6 cycles of chemotherapy was compared between the two groups. Univariate and multivariate logistic regression analyses were used to analyze the associations of age, gender, alcohol history, primary tumor location, tumor differentiation, tumor staging, chemotherapy courses, and syndrome types with the occurrence of gastrointestinal adverse reactions, liver function damage, bone marrow suppression and peripheral neurotoxicity in colorectal cancer patients who have completed 2, 4, 6 and more than 6 cycles of oxaliplatin-containing chemotherapy. ResultsThere were significant differences in the occurrence of gastrointestinal reactions after completing 2, 4, 6 and more than 6 cycles of chemotherapy between the two groups (P<0.01), with much more severe conditions in SKYDS group than non-SKYDS group (P<0.01). There was no significant difference in liver function damage and bone marrow suppression between groups (P>0.05). There were statistically significant differences in the occurrence of peripheral neurotoxicity after completion of 2 cycles (P=0.044), 4 cycles (P=0.002) and more than 6 cycles (P<0.001) of chemothe-rapy, with higher rate in SKYDS group than the non-SKYDS group (P<0.05). Univariate analysis showed that female, patients with stage Ⅲ tumors and patients having completed ≥ 6 cycles of chemotherapy had a higher incidence of bone marrow suppression (P<0.05), and patients with SKYDS had a higher incidence of gastrointestinal reactions (P<0.001). Patients with a history of drinking, stage Ⅳ cancer, and ≥6 cycles of chemotherapy had a higher incidence of liver function injury (P<0.05). Patients with stage Ⅲ cancer, ≥6 cycles of chemotherapy, and SKYDS had a higher incidence of peripheral neurotoxicity (P<0.05). Multivariate analysis showed that the risk factor for bone marrow suppression was chemotherapy ≥6 cycles (P=0.001), and SKYDS was the risk factor for gastrointestinal reaction (P<0.001). The risk factor for liver function damage was tumor stage Ⅳ (P=0.001) and SKYDS (P=0.039). All variables had no significant correlation with the occurrence of peripheral neurotoxicity. ConclusionFor colorectal cancer patients, being diagnosed with SKYDS is a risk factor for developing gastrointestinal adverse reactions and peripheral neurotoxicity following chemotherapy with an oxaliplatin-based regimen.
5.Investigating the duration of antibody response in vaccination:Current progresses and challenges
Jiajie LI ; Shuyang WANG ; Sijie WANG ; Sixuan MA ; Zhenglin JI ; Wanli LIU
Chinese Journal of Immunology 2024;40(8):1569-1578
In the earliest days,the idea that surviving a single infection often resulted in lifelong immunity to the infecting pathogen was recorded and then led to the discovery of vaccination.We have now confirmed that such protection is primarily based on the generation of immunological memory in antibody response.With the wide implementation of more and more vaccines around the world,it is well documented that different vaccines have different potential regarding to the duration of antibody response.In clinical observations,live-attenuated vaccines often elicit long-term immunity but are also accompanied with risks in safety that are hard to avoid.In order to develop novel vaccines with both excellent potential in eliciting antibody memory and low safety risk,it is critical to further investigate the mechanism of antibody memory in the perspective of immunology.Antibody memory is mediated by certain long-lived B cells:long-lived plasma cell can secret antibody to maintain serum antibody titer while memory B cell contributes to the rapid immune response during the secondary encounter of pathogens.Cellular and molecular processes that drive the production of long-lived plasma cells and memory B cells are subjects of intensive research and have important implications for global health.Several factors in the vaccine would indeed affect and regulate these processes,including the antigen valency,vaccine kinetics and the signal integration of both antigen and danger molecules.Many studies have focused on strategies to manipulate these factors to improve or develop new vaccines.Here,we will summarize our current knowledge on how the component in vaccines will affect their potential in generating and sustaining antibody memory,and also point out the challenges we face in the route of developing a"perfect"vaccine.
6.Trends in mortality of malignant tumors in Ningbo City from 2002 to 2022
WANG Yong ; YING Yanyan ; CHEN Jieping ; CUI Jun ; BAO Kaifang ; LI Sixuan ; ZHU Yinchao ; WANG Sijia ; XU Dian ; FENG Hongwei
Journal of Preventive Medicine 2023;35(6):496-500
Objective:
To investigate the trends in mortality of malignant tumors in Ningbo City, Zhejiang Province from 2002 to 2022, so as to provide the evidence for formulating malignant tumor control strategies in Ningbo City. Methods The data regarding the mortality of malignant tumors in Ningbo City from 2002 to 2022 were collected through the Ningbo Municipal Death Cause Monitoring System, and the crude mortality and age-specific mortality of malignant tumors were calculated in Ningbo City. The mortality of malignant tumors was standardized by the population of the sixth National Population Census in China in 2010 (Chinese-standardized mortality) and the world standard population in 1960 (world-standardized mortality). The trends in mortality of malignant tumors were evaluated with annual percent change (APC) and average annual percent change (AAPC).
Methods:
The data regarding the mortality of malignant tumors in Ningbo City from 2002 to 2022 were collected through the Ningbo Municipal Death Cause Monitoring System, and the crude mortality and age-specific mortality of malignant tumors were calculated in Ningbo City. The mortality of malignant tumors was standardized by the population of the sixth National Population Census in China in 2010 (Chinese-standardized mortality) and the world standard population in 1960 (world-standardized mortality). The trends in mortality of malignant tumors were evaluated with annual percent change (APC) and average annual percent change (AAPC).
Results:
The crude mortality of malignant tumors was 186.43/105 to 221.24/105 in Ningbo City from 2002 to 2022, which showed a tendency towards a rise (AAPC=0.76%), and both the Chinese- (AAPC=-2.64%) and world-standardized mortality (AAPC=-2.74%) appeared a tendency towards a decline (all P<0.05). The world-standardized mortality of malignant tumors presented three changes in Ningbo City from 2002 to 2022, with a more remarkable decline from 2011 to 2018 (APC=-3.53%) than from 2002 to 2011 (APC=-2.10%) and from 2018 to 2022 (APC=-2.00%) (all P<0.05). The annual decline in mortality of malignant tumors was higher in men (Chinese-standardized mortality: AAPC=-2.68%; world-standardized mortality: AAPC=-2.75%) than in women (Chinese-standardized mortality: AAPC=-2.45%; world-standardized mortality: AAPC=-2.57%), and higher in urban areas (Chinese-standardized mortality: AAPC=-2.85%; world-standardized mortality: AAPC=-2.92%) than in rural areas (Chinese-standardized mortality: AAPC=-2.45%; world-standardized mortality: AAPC=-2.57%) (all P<0.05). The mortality of malignant tumors appeared a tendency towards a rise with age in Ningbo City, with the highest mortality in residents at ages of 85 years and older (1 447.13/105). Death from malignant tumors were responsible for 31.86% of all causes of death in Ningbo City, and the five most common causes of cancer death included lung cancer, liver cancer, gastric cancer, colorectal cancer and esophageal cancer. In addition, the world-standardized mortality of pancreatic cancer (AAPC=3.92%), prostate cancer (AAPC=4.71%), and cervical cancer (AAPC=1.60%) appeared a tendency towards a rise in Ningbo City (all P<0.05).
Conclusions
The crude mortality of malignant tumors appeared a tendency towards a rise in Ningbo City from 2002 to 2022, while the standardized mortality showed a tendency towards a decline. Management of malignant tumors should be given a high priority among men and rural residents, and lung cancer, liver cancer, gastric cancer, colorectal cancer and esophageal cancer should be emphasized.
7.Trends in incidence and mortality of gastric cancer in Ningbo City from 2011 to 2022
WANG Yong ; BAO Kaifang ; WANG Sijia ; CHEN Jieping ; CUI Jun ; YING Yanyan ; ZHU Yinchao ; LI Sixuan ; XU Dian
Journal of Preventive Medicine 2023;35(7):557-562
Objective:
To investigate the trends in incidence and mortality of gastric cancer in Ningbo City, Zhejiang Province from 2011 to 2022, so as to provide insights into improving gastric cancer control strategy.
Methods:
The incidence and mortality of gastric cancer in Ningbo City from 2011 to 2022 were collected through Ningbo Municipal Chronic Disease and Cause of Death Monitoring System. The incidence and mortality of gastric cancer were calculated, and standardized by the data from the Sixth Chinese National Population Census in 2020 (Chinese-standardized rate) and the world standard population first introduced by Segi in 1960 (world-standardized rate). The trends in incidence and mortality of gastric cancer were evaluated using annual percent change (APC) and average annual percent change (AAPC).
Results :
The crude incidence of gastric cancer was 45.69/105 in Ningbo City from 2011 to 2022, with no significant changing patterns seen during the study period (AAPC=-0.02%, P>0.05), and the Chinese- and world-standardized incidence of gastric cancer was 28.61/105 and 21.87/105, which both appeared a tendency towards a decline (AAPC=-3.19% and -3.05%, both P<0.05). The crude, Chinese-standardized and world-standardized mortality rates of gastric cancer were 28.56/105, 17.07/105 and 12.57/105, respectively, all showing a tendency towards a decline (AAPC=-3.00%, -6.26% and -6.34%, all P<0.05). The Chinese- and world-standardized incidence and mortality of gastric cancer all appeared a tendency towards a decline in urban (AAPC=-2.72%, -2.53%, -5.91% and -5.96%, all P<0.05) and rural areas (AAPC=-3.61%, -3.53%, -6.79% and -6.89%, all P<0.05), and the Chinese- and world-standardized incidence and mortality of gastric cancer were significantly higher among urban residents than among rural residents. The Chinese- and world-standardized incidence and mortality of gastric cancer all appeared a tendency towards a decline among men (AAPC=-3.18%, -3.00%, -5.82% and -5.91%, all P<0.05) and women (AAPC=-2.98%, -2.90%, -7.12% and -7.12%, all P<0.05), and the Chinese- and world-standardized incidence and mortality of gastric cancer was significantly higher among men than among women. In addition, the crude incidence and mortality of gastric cancer both appeared a tendency towards a rise with age among residents in Ningbo City (both P<0.05).
Conclusions
The incidence and mortality of gastric cancer both appeared a tendency towards a decline in Ningbo City from 2011 to 2022; however, the incidence and mortality remained high. Males and urban residents should be given a high priority for gastric cancer control, and gastric cancer screening should be strengthened among individuals at ages of 40 years and older.
8.Long-term outcomes of additional surgery versus non-gastrectomy treatment for early gastric cancer after non-curative endoscopic submucosal dissection: a meta-analysis
Sixuan LI ; Xueli TIAN ; Jingyao WEI ; Yanyan SHI ; Hua ZHANG ; Yonghui HUANG
Chinese Medical Journal 2023;136(5):528-535
Background::Endoscopic resection is increasingly used in the treatment for early gastric cancer (EGC); however, about 15% of endoscopic submucosal dissection (ESD) cases report non-curative resection. The efficacy of different remedial interventions after non-curative ESD for EGC remains controversial. This meta-analysis aimed to compare the long-term outcomes of additional surgery and non-gastrectomy treatment for EGC patients who underwent non-curative ESD.Methods::All relevant studies published up to October 2021 were systematically searched in the PubMed, Web of Science, and Embase databases. The medical subject headings terms "early gastric cancer," "gastrectomy," "endoscopic submucosal dissection," and their related free keywords were used to search relevant articles without restrictions on regions, publication types, or languages. The Newcastle–Ottawa Quality Assessment Scale was used to evaluate the quality of the included studies. Odds ratios (ORs) with 95% confidence intervals (CIs) of 5-year overall survival (OS), disease-specific survival (DSS), disease-free survival (DFS) and hazard ratios (HRs) with 95% CIs of OS were calculated using a random- or fixed-effects model.Results::This meta-analysis included 17 retrospective cohort studies with 5880 patients, of whom 3167 underwent additional surgery and 2713 underwent non-gastrectomy. We found that patients receiving additional gastrectomy had better 5-year OS (OR = 3.63, 95% CI = 3.05–4.31), DSS (OR = 3.22, 95% CI = 2.22–4.66), and DFS (OR = 4.39, 95% CI = 1.78–10.82) outcomes than those receiving non-gastrectomy treatments. The pooled HR also showed that gastrectomy following non-curative ESD significantly improved OS (HR = 0.40, 95% CI = 0.33–0.48). In addition, elderly patients benefited from additional surgery in consideration of the 5-year OS (HR = 0.54, 95% CI= 0.41–0.72).Conclusions::Compared with non-gastrectomy treatments, additional surgery offered better long-term survival outcomes for patients with EGC who underwent non-curative ESD.
9.Clinical study of induction chemotherapy followed by allogeneic hematopoietic stem cell transplantation in the treatment of FLT3-ITD + acute myeloid leukemia with normal karyotype
Fang LI ; Yanping LIU ; Han ZHU ; Ming HONG ; Sixuan QIAN ; Yu ZHU ; Wenyi SHEN ; Lijuan CHEN ; Guangsheng HE ; Hanxin WU ; Hua LU ; Jianyong LI ; Kourong MIAO
Chinese Journal of Hematology 2023;44(3):230-235
Objective:To assess the efficacy of induction chemotherapy followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of FLT3-ITD + acute myeloid leukemia (AML) with normal karyotype. Methods:The clinical data of FLT3-ITD + AML patients with normal karyotype in the First Affiliated Hospital of Nanjing Medical University from Jan 2018 to March 2021 were retrospectively analyzed. Results:The study included 49 patients with FLT3-ITD +AML, 31 males, and 18 females, with a median age of 46 (16-59) years old. All patients received induction chemotherapy, and 24 patients received sequential allo-HSCT (transplantation group) . The median follow-up time was 465 days, the one-year overall survival (OS) from diagnosis was (70.0 ± 7.4) %, and one-year disease-free survival (DFS) was (70.3±7.4) %. The one-year OS was significantly different between the transplantation group and the non-transplantation group [ (85.2 ± 7.9) % vs (52.6 ± 12.3) %, P=0.049]. but one-year DFS [ (84.7 ± 8.1) % vs (55.2 ± 11.9) %, P=0.061] was not. No significance was found in one-year OS between patients with low-frequency and high-frequency FLT3-ITD + ( P>0.05) . There were 12 patients with high-frequency FLT3-ITD + in the transplantation and the non-transplantation groups, respectively. The one-year OS [ (68.8 ± 15.7) % in the transplantation group vs (26.2 ± 15.3) % in the non-transplantation group, P=0.027] and one-year DFS [ (45.5 ± 21.3) % in the transplantation group vs (27.8±15.8) % in the non-transplantation group, P=0.032] were significantly different between the two groups. Conclusion:Induction chemotherapy followed by allo-HSCT can enhance the prognosis of FLT3-ITD + patients, particularly those with FLT3-ITD high-frequency mutation.
10.Trend in mortality of liver cancer in Ningbo City from 2002 to 2021
Yanyan YING ; Yong WANG ; Jieping CHEN ; Sixuan LI ; Kaifang BAO ; Sijia WANG ; Guozhang XU
Journal of Preventive Medicine 2022;34(12):1218-1223
Objective:
To analyze the trend in the mortality of liver cancer in Ningbo City from 2002 to 2021, so as to provide the evidence for improving the liver cancer control measures.
Methods:
The liver cancer mortality data in Ningbo City from 2002 to 2021 were collected from Ningbo Municipal Chronic Disease Surveillance System. The crude mortality and standardized mortality by the 2 000 national population census data of liver cancer were estimated, and the proportion of concomitant diseases was analyzed among all dead patients with liver cancer. In addition, the trends in liver cancer mortality were analyzed with annual percentage change (APC) and average annual percentage change (AAPC).
Results:
Both the crude and standardized mortality of liver cancer appeared a tendency towards a decline year by year in Ningbo City from 2002 to 2021, with AAPC of -3.47% (95%CI: -4.08% to -2.85%, P<0.001) and -6.56% (95%CI: -7.25% to -5.87%, P<0.001), and a the decline in liver cancer mortality was larger during the period between 2006 and 2021 than during the period between 2002 and 2006. The annual mean crude and standardized mortality of liver cancer was 35.39/105 and 20.98/105, and the crude mortality of liver cancer was 52.69/105 in men and 18.13/105 in women, respectively. After adjustment for age, the risk of liver cancer mortality was 3.03 (95%CI: 2.96-3.09) times greater among men than among women, and the mortality of liver cancer appeared a tendency towards a rise with age (χ2trend=45 684.254, P<0.001). Concomitant diseases were found among 9 985 dead cases with liver cancer (24.44%), and the concomitant diseases mainly included digestive system diseases (predominantly liver diseases) and infectious and parasitic diseases (predominantly virus hepatitis).
Conclusions
The mortality of liver cancer appeared a tendency towards a decline in Ningbo City from 2002 to 2021, and men and middle-aged and elderly residents were at high risk of liver cancer mortality. Digestive system diseases and infectious and parasitic diseases were predominant concomitant diseases among dead patients with liver cancer.


Result Analysis
Print
Save
E-mail